Please assess the completion status of the following clinical trial:

Trial Title: Canadian Biomarker Integration Network for Depression Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
For Depressed patients:~Inclusion Criteria:~* Outpatients who are 18-60 years of age~* Meet DSM-IV-TR criteria for Major Depressive Episode in Major Depressive Disorder by the MINI~* Episode duration ≥ 3 months~* Free of psychotropic medications for at least 5 half-lives (i.e. 1 week for most antidepressants, 5 weeks for fluoxetine) before baseline Visit 1~* MADRS ≥ 24~* Fluency in English, sufficient to complete the interviews and self-report questionnaires~Exclusion Criteria:~* Any Axis I diagnosis other than MDD that is considered the primary diagnosis~* Bipolar I or Bipolar II diagnosis~* Presence of a significant Axis II diagnosis (borderline, antisocial)~* High suicidal risk, defined by clinician judgment~* Substance dependence/abuse in the past 6 months~* Presence of significant neurological disorders, head trauma or other unstable medical conditions~* Pregnant or breastfeeding~* Failure of 3 or more adequate pharmacologic interventions (as determined by the Antidepressant Treatment History Form)~* Started psychological treatment within the past 3 months with the intent of continuing treatment~* Patients who have previously failed escitalopram or showed intolerance to escitalopram and patients at risk for hypomanic switch (i.e. with a history of antidepressant hypomania)~Inclusion criteria for Healthy Controls:~* 18 to 60 years of age~* No history of Axis I or Axis II disorders, as determined by the MINI.~* Fluency in English, sufficient to complete the interviews and self-report questionnaires.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- escitalopram (10-20mg) (Type: ACTIVE_COMPARATOR): Patients are on escitalopram for 8 weeks. At Week 8, patients will be assessed as 'responders' or 'non-responders'. 'Responders' will continue on escitalopram until study endpoint.
- aripiprazole (2-10mg) (Type: ACTIVE_COMPARATOR): At Week 8, patients assessed as 'non-responders' will be given aripiprazole as an add-on treatment to escitalopram.

Based on this trial design, predict the completion outcome and termination type (if applicable).